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Abstract
Genome-wide association studies have identified thousands of loci for common diseases, but for
the majority of these, the mechanisms underlying disease susceptibility remain unknown. Most
associated variants are not correlated with protein-coding changes, suggesting that polymorphisms
in regulatory regions are likely to contribute to many disease phenotypes. The careful examination
of gene expression and its relationship to genetic variation has thus become a critical next step in
the elucidation of the genetic basis of common disease. Cell context is a key determinant of gene
regulation; but to date, the challenge of collecting large numbers of diverse tissues in humans has
largely precluded such studies outside of a few easily sampled cell types. Here we describe the
Genotype-Tissue Expression (GTEx) project, which will establish a resource database and
associated tissue bank for the scientific community to study the relationship between genetic
variation and gene expression in human tissues.
URLs. GWAS, http://www.genome.gov/gwastudies; GTEx LDACC Data Portal, http://www.broadinstitute.org/gtex; caHUB, http://
cahub.cancer.gov/; and http://biospecimens.cancer.gov/resources/sops/default.asp; dbGaP, http://www.ncbi.nlm.nih.gov/projects/gap/
cgi-bin/study.cgi?study_id=phs000424; NIH Common Fund, http://commonfund.nih.gov/GTEx/ and http://genome.gov/gtex.; NCBI
GTEx eQTL Browser, http://www.ncbi.nlm.nih.gov/gtex/test/GTEX2/gtex.cgi/; Request for Information, http://grants.nih.gov/grants/
guide/notice-files/NOT-RM-12-028.html; seeQTL (http://www.bios.unc.edu/research/genomic_software/seeQTL/, and SCAN http://
biospecimens.cancer.gov/resources/sops/default.asp; Community Resource Policy, http://gwas.nih.gov/03policy2.html. Sharing Data
from Large-Scale Biological Research Projects: A System of Tripartite Responsibility, http://www.wellcome.ac.uk/About-us/
Publications/Reports/Biomedical-science/WTD003208.htm; NIH Implementation Group Members, http://commonfund.nih.gov/
GTEx/members.aspx.
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In the past decade, genome-wide association studies (GWAS) have documented a strong
statistical association between common genetic variation at thousands of loci and more than
250 human traits1. Yet the functional effect of most GWAS-implicated variants remains
largely unexplained. The finding that nearly 90% of these sites occur outside of protein
coding sequences2 suggests that many associated variants may instead play a role in gene
regulation.
Expression quantitative trait loci (eQTL) mapping offers a powerful approach to elucidate
the genetic component underlying altered gene expression3. Studies primarily in blood, skin,
liver, adipose, and brain indicate that eQTLs are common in humans4–6. Genetic variation
can also influence gene expression through alterations in splicing, non-coding RNAs, and
RNA stability7–9. eQTLs regulating nearby or distant genes are commonly referred to as cis-
eQTLs and trans-eQTLs, respectively3. Gene expression is differentially regulated across
tissues, and many human transcripts are expressed in a limited set of cell types or during a
limited developmental stage. Several studies have reported tissue-specific eQTLs10,11, and
combining eQTL studies with network analyses across multiple tissues has helped to define
complex networks of gene interactions12,13.
Complementing eQTL data with other molecular phenotypes, such as epigenomic assays14,
on the same tissues, and linking to resources such as ENCODE15, will provide a powerful
means of dissecting gene regulatory and higher-order networks across multiple tissues. This
will be important because evaluation of the functional consequences of a disease-associated
SNP would ideally be assayed in a disease-relevant cell context. However, for most tissue
types, human biospecimens are very difficult to obtain from living donors (i.e. brain, heart,
pancreas, etc.), and most eQTL studies to date have been performed with RNA isolated from
immortalized lymphoblasts or lymphocytes6 and a few additional readily sampled tissues.
To fully enable this critical next step in the study of the genetic basis of common disease, it
will be of enormous value to have a resource of blood samples from individuals who have
been comprehensively genotyped (and eventually completely sequenced) and linked to
genome-wide gene expression patterns across a wide range of tissue types. As a first step,
this resource would enable the research community to perform a comprehensive search for
eQTLs (both tissue-type specific and across tissue types) and establish their association with
disease-associated variants from GWAS or sequencing studies. Eventually, as other
molecular phenotypes are added, the relationship between genetic variation and gene
expression can expand to include correlations with epigenetics, proteomics, etc. While such
a catalog would have been unthinkable a few years ago, new genomic technologies are now
making the problem approachable.
This convergence of unmet scientific need and new technology prompted an NIH workshop
held in June 2008 to discuss the advisability and feasibility of a large-scale public resource
for human genetic variation and gene expression across tissues. Based on the output of this
workshop and ongoing consultation, NIH Program staff developed the concept of the
Genotype-Tissue Expression (GTEx) project (See Box 1). Many of the specifics of the pilot
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project described here were contributed by funded investigators and were influenced by
early, experimental biospecimen collections.
Design of the GTEx Project
The GTEx Project of the NIH Common Fund aims to establish a resource database and
associated tissue bank in which to study the relationship between genetic variation and gene
expression, and other molecular phenotypes, in multiple reference tissues (Supplementary
Figure 1). The GTEx project began with a 2.5-year pilot phase to test the feasibility of
establishing a rapid autopsy program that would yield high-quality nucleic acids and robust
gene expression measurements. Having met milestones of donor enrollment, RNA quality,
and eQTL findings, the project is scaling up to include approximately 900 post-mortem
donors by the end of 2015. The power to detect eQTLs is dependent on multiple factors that
are difficult to quantify precisely, but values over a range of effect sizes and allele
frequencies are described in Figure 1.
GTEx donors are identified through low-post-mortem-interval (PMI) autopsy or organ and
tissue transplant settings. To compare the quality of results from autopsy vs. surgically
derived tissue, a small subset of tissue types routinely discarded during a surgical
amputation, such as skin, fat, and muscle, are also being collected. In addition, peripheral
blood samples are collected and used as both a source of DNA for whole-genome single-
nucleotide polymorphism (SNP) and copy number variant (CNV) genotyping and to
establish lymphoblastoid cell lines. Skin samples are collected from the same region of the
lower leg both for measurement of gene expression and to establish fibroblast cultures.
Quantification of gene expression is derived primarily from massively parallel sequencing of
RNA, but some pilot-phase tissues were analyzed both by sequencing and by gene
expression array to enable a technology comparison. eQTLs will be identified and made
accessible to the scientific community through the National Center for Biotechnology
(NCBI) GTEx database and a GTEx data portal. In addition, the GTEx raw data will be
made available through the database of Genotypes and Phenotypes (dbGaP) on a periodic
basis.
The GTEx structure during the pilot phase is depicted in Supplementary Figure 2, and
includes entities for biospecimen acquisition, processing, storage, and verification; a study
on ethical, legal, and social issues (ELSI); the Laboratory, Data Analysis and Coordinating
Center (LDACC); the GTEx-eQTL browser; novel statistical methods development grants;
and a Brain Bank. The scale-up is organized similarly to the pilot; the current structure and
information about funding opportunities are available on the NIH Common Fund web site.
Biospecimen acquisition
These functions are designed and organized under the National Cancer Institute’s (NCI)
cancer Human Biobank (caHUB). caHUB has enrolled under contract several Biospecimen
Source Sites (BSS), a Comprehensive Biospecimen Resource (CBR), a Comprehensive Data
Resource (CDR), and Pathology and Quality Management teams to perform acquisition of
biospecimens and associated data. All Standard Operating Procedures for donor enrollment
and sample collection are available on the caHUB web site.
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Donors of any racial and ethnic group and sex who are age 21–70 in whom biospecimen
collection can start within 24 hours of death are eligible. There are few medical exclusionary
criteria: human immunodeficiency virus (HIV) infection or high-risk behaviors, viral
hepatitis, metastatic cancer, chemotherapy or radiation therapy for any condition within the
past 2 years, whole blood transfusion in past 48 hours, or body mass index ≥ 35 or ≤18.5.
Each BSS collects, where feasible, aliquots from many pre-designated tissue sites and
organs (Supplementary Table 1), including the brain of deceased donors who were not on a
ventilator for the 24 hours prior to death. Immediately after excision, most of the aliquots are
stabilized in a solution containing alcohols (ethanol and methanol), acetic acid, and a soluble
organic compound that fixes primarily by protein precipitation (PAXgene Tissue, Qiagen)
and shipped to the CBR. Only blood samples and full-thickness skin biopsies are sent
unfixed to the LDACC for cell line initiation. The majority of the brain and brainstem are
also left unfixed and shipped overnight on wet ice to a brain bank. Further details of donor
recruitment and sample collection, including Standard Operating Procedures, are available
through caHUB.
Pathology review and clinical annotation
At the CBR, an aliquot from each sampled tissue is paraffin embedded, sectioned, and
stained for histological analysis. A dedicated team of pathologists reviews slides from all
tissue specimens to verify the organ source and to characterize both general pathological
characteristics, such as autolysis, as well as organ-specific pathological states and
inflammation. Of course not all organs will be entirely normal, but donor eligibility is broad
and not restricted to specific diseases or conditions, and it is expected that many organs will
be free of major disease processes. An aliquot of each tissue, fixed and stabilized in
PAXgene Tissue solution, but without paraffin embedding, is sent to the LDACC for
molecular analysis. Policies and systems for accessing stored tissue samples are currently
being developed. The CBR's histologic sections are viewed as digitally scanned images,
which allow precise annotations to be made to indicate where downstream studies, e.g.,
tissue microarrays and laser capture microextraction, on selected portions of a specimen can
focus (e.g., lymphoid nodules in ileal mucosa or the squamous epithelium of the esophageal
mucosa).
The clinical data collected for each GTEx donor belongs to one of two categories: donor-
level data or sample level data. Donor level data encompasses all clinical measures of the
donor, which includes basic demographics, medication use, medical history, laboratory test
results, and the circumstances surrounding the donor’s death. These data are collected from
the donor (surgical) or next of kin (post-mortem) and verified against the donor’s medical
record when readily available. Summary frequency distributions for clinical variables are
available in dbGaP. Sample level data are attributes belonging to each sample collected and
include the tissue type, ischemic time, comments from the prosector and pathology reviewer,
and process metadata such as batch ID and the amount of time spent in the PAXgene
fixative. Both donor and sample level data are checked for quality and completeness before
being released.
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Brain Bank
Aliquots from a single region of the cortex and cerebellum are sampled and preserved in
PAXgene Tissue at the BSS, while the remaining whole brain, with attached brain stem and
cervical spinal cord, when possible, is shipped on wet ice to an NIH-funded brain bank.
After sectioning at the Brain Bank, frozen samples from additional anatomical regions of the
brain are analyzed at the LDACC and the remaining brain banked for future uses.
Laboratory, Data Analysis, and Coordinating Center (LDACC)
The LDACC performs nucleic acid extractions and quality assessment, DNA genotyping,
and RNA expression analysis. The LDACC integrates results of the molecular analysis with
phenotype data, performs eQTL analysis, deposits data into dbGaP, and provides a portal for
open access data, Standard Operating Procedures for sample processing and data generation,
and results.
DNA is genotyped using the Illumina Human Omni5M-Quad BeadChip to collect whole
genome SNP and CNV information from each donor’s blood sample (or an alternate tissue if
blood is unavailable). This assay contains over 4 million probes, with robust coverage of
both SNPs and CNVs. DNA is also characterized using the Illumina HumanExome
BeadChip to obtain high quality SNP calls within coding regions.
A portion of each tissue is processed for RNA and DNA extraction, quantification, and
quality assessment. Extraction protocols that preserve both messenger RNA and microRNA
are being used, and are available on the data portal. For measurement of gene expression,
the LDACC analyzed approximately 1,000 samples using both microarrays (Affymetrix
Human Gene 1.1 ST Array) and next-generation RNA sequencing (Illumina HiSeq 2000),
during the pilot, to establish comparability of these methods using post-mortem tissue. The
RNA-Seq uses a 76 base, paired?end Illumina TruSeq RNA protocol, averaging ~50 million
aligned reads per sample. This read depth was selected to maximize sequencing value with
the budget available, and should make it possible to accurately measure moderate- and some
low-expressed transcripts, but will have limited ability to accurately quantify rare transcripts
and splice isoforms. It should provide gene expression measurements equal to or more
accurate than expression arrays and with a higher dynamic range (i.e. coefficient of variation
<0.1 for at least 12,000 genes; Supplementary Figure 3). RNA-Seq allows one to evaluate
allele-specific expression in heterozygous individuals, improving the power to identify cis
regulatory variants. With the target depth of 50 million aligned reads, we expect to be
powered to detect ASE in the top tertile of expressed genes (Supplementary Figure 4). As
the cost of RNA-Seq drops, greater read depth will be possible, but with current resources
the strategy is to maximize the number of samples analyzed.
The fresh blood and full-thickness skin samples are used to establish Epstein-Barr virus
(EBV)-transformed lymphoblastoid cell lines and primary fibroblast cell lines. Since many
existing human eQTL studies have used EBV-immortalized cell lines, having these lines in
addition to all the other peripheral tissues will allow researchers to evaluate the limitations
of using only a lymphoblastoid cell line.
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GTEx-eQTL Browse
eQTLs are available and queryable in browsers hosted both at the LDACC GTEx portal and
at NCBI who will verify the eQTL results provided by the project and both display them and
make them available to other genome browsers and the scientific community.
Statistical analysis and methods development
To promote the analysis of eQTL results across a wide range of human tissues, the NIH
funded five centers to develop improved methods for statistical analysis. Investigators
funded through this RFA form an analysis consortium that will provide innovative
approaches to analyses of GTEx data and other similar datasets. Investigators also
collaborate with the LDACC to perform data quality assessment/quality control before
release into dbGaP. The initial GTEx Consortium publications, anticipated in 2013, will
include genome-wide analysis of cis- and trans-eQTLs, allele-specific expression, splicing
quantitative trait loci, and a comparison of array and RNA-Seq based gene expression
results.
Sample access and molecular analyses
The NIH is interested in making maximal use of this unique biospecimen resource, rich with
clinical and genomic information. An access system including mechanisms for requesting
samples is under development. Except for the fibroblast and lymphoblastoid cell lines,
biospecimens are of limited quantity and are non-renewable. Potential uses that are
comprehensive (genomic vs. single gene or small gene networks, proteomic vs. single
proteins or small networks of proteins, etc.) and complementary to existing gene expression
and variation data, are preferred. Scientific questions that are equally well addressed using
other sample sets will probably not be suitable, while those that take full advantage of the
unique aspects of GTEx, such as the multiple tissues from each donor and the gene
expression information, are particularly sought. All data resulting from analysis of GTEx
samples must be made widely available to the scientific community. In addition to scientific
review, all proposals to use GTEx samples would also go through a Biospecimen Access
Committee (currently being formed).
Power Analysis
To set expectations and guide design of the full GTEx project, we built a framework to
evaluate the statistical power to detect eQTLs. The statistical power depends on various
parameters, some known more accurately than others. These parameters include the number
of donors, the eQTL effect size, the noise, as well as the significance threshold, which is
based on the number of hypotheses tested. Assuming we are testing cis-eQTLs between each
of the 20,000 genes and 10 non-redundant cis-SNPs (on average) in vicinity (±100 kb) of
each gene, the overall number of hypotheses is 200,000. Therefore, using a Bonferroni
correction, we set the significance threshold, α, to be 0.05/200,000. For a trans-eQTL
analysis, a conservative estimate of α is ~ 5×10−13 (20,000 transcripts tested against 5
million loci). We model the expression data as log-normally distributed with a log standard
deviation of 0.13 within each genotype class. This level of noise is based on estimates from
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initial GTEx data. The effect size depends both on the minor allele frequency of the SNP
(MAF) and the actual log expression change between genotype classes (denoted by Δ).
Figure 1a shows the statistical power of a cis-eQTL analysis, and Figure 1b a trans-eQTL
analysis, using an ANOVA statistical test as a function the number of subjects and the minor
allele frequency (MAF), and assumes Δ=0.13 (equivalent to detecting a log-expression
change similar to the standard deviation within a single genotype class). A final GTEx
resource of 900 or more donors would realistically yield ~750 samples of any given tissue,
since not all organs are available for collection from each donor. At an effective sample size
of 750, we would have 80% power to detect cis-eQTLs with MAF as low as 2% and trans-
eQTLs with MAF as low as 4%. The statistical power may be higher using methods that
leverage the fact that multiple tissues are collected and analyzed for each donor. Since the
underlying parameters are merely rough estimates, we repeated the power analysis with
different values (10 to 20 SNPs, 20,000–100,000 transcripts) and show that 80% power is
achieved for MAF between 3 and 4% for cis-eQTLs. For trans-eQTLs, this range in
transcripts results powered MAFs between 4 and 5% (Supplementary Figure 5).
Data release, access, and publication policy
GTEx is designated by NIH as a community resource and as such aims to share as much of
the data (some of which will be unique and identifiable) as rapidly as possible, following
NIH guidelines. It is recognized that quantifying the risk of identifying a donor based on
genetic and other information lies on a continuum and is a complex issue dependent on
many factors, such as other sources of data and evolving analytical methods16,17. Sharing of
any information unique to an individual carries a small but difficult to define risk of
identifiability, but this must be balanced with the benefits of data sharing to advance
science.
Some data from the GTEx project is openly available, meaning that it can be accessed
directly through the Internet. However, in order to reduce risks of sharing potentially
identifying data, some data elements are available to the scientific community only through
a controlled-access system, NCBI’s dbGaP. Standard Operating Procedures (SOPs), data
collection instruments, histopathological interpretations, molecular data that does not
provide direct genetic variation information (e.g., expression arrays, summary sequence-
based gene expression estimates stripped of variant information, eQTL results), laboratory
processing variables (e.g., cDNA library preparation methods), and a very limited set of
medical and socio-demographic variables (e.g., sex, age at death in intervals) will be openly
available. The LDACC will host an open access data portal while specimen acquisition
SOPs and associated data collection instruments will be available through caHUB. Other
medical and social history information, molecular results that contain direct genetic
variation information (e.g., SNP genotyping files, RNA-Seq reads) and summary results that
allow accurate inference of allele frequencies18 will be available only through controlled
access. Direct HIPAA identifiers, including dates that include month and day, will not be
available through either open or controlled access.
Implementation of these data release policies and processes are a topic of ongoing
discussion and may need to be modified as risks of identifiability are better quantified for
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various data types, and as the size of the study increases. After initial processing of raw data
(such as sequence reads and genotyping files), basic data quality checks are completed by
the LDACC and statistical methods investigators, then data is released immediately through
dbGaP. The first dbGaP data release, consisting of data from 62 individuals, occurred in
June 2012. For the pilot phase of the project, which concluded in January 2013, the data set
comprises genotype data from 190 individuals from which 1814 total tissues (from 47
separate tissue sites) were profiled by RNA-seq to a median depth of 80 million aligned
reads. These data are in the process of being released to dbGaP, and we anticipate further
releasing data two to four times per year until the project is completed. We expect total
enrollment to over 400 by 2013, over 700 in 2014, and approximately 900 by the end of
2015.
The GTEx project falls under the Ft. Lauderdale meeting principles of rapid, pre-publication
data release. These principles involve publication of a manuscript near the outset to describe
the scope and vision of the project and plans to make data available. The continued success
of rapid pre-publication data release relies on the scientific community to respect the data
producer’s interest to publish a full analysis of their data first. While others are free to
analyze GTEx data immediately upon release, the GTEx consortium envisions publication
of both a comprehensive description of the sample acquisition and processing system and a
series of genome-wide analyses of genetic variation and gene expression, as described in the
“Statistical Analysis and Development of Methods” section.
Ethical, legal and social implications (ELSI)
The GTEx project involves potentially sensitive recruitment, Institutional Review Board
(IRB), and consent issues, particularly for deceased donors and their families. The collection
of biospecimens from deceased individuals is not legally classified as human subjects
research under 45 CFR 46; nonetheless, the depth of the genetic information obtained from
deceased donor specimens has direct implications for donor patient families. In recognition
of this, sites were required to obtain written or recorded verbal authorization from next-of-
kin for deceased donor participation in GTEx, typically through an addendum or
modification to an existing authorization form for research donation of tissues and organs. It
included statements common in consent forms such as the intention to perform genetic
analyses, establish cell lines, and to share data with the scientific community. Work
underway is more closely identifying familial concerns and may result in a modification to
authorization. Living surgery donors participate only after full, written informed consent is
obtained.
In addition, an ELSI study of the consent/authorization process is being carried out at one
BSS, to assess both the effectiveness of the consent/authorization process in informing
participants of the risks and benefits of the study and its potential psychosocial impact on
donors and/or their families. The ELSI study is fully integrated with the biospecimen
collection efforts and will be expanded during the scale up of the GTEx program.
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Conclusions
A large-scale GTEx resource will be a powerful tool to unravel the complex patterns of
genetic variation and gene regulation across diverse human tissue types. The GTEx project
will aid in the interpretation of GWAS findings for translational research by providing data
and resources on eQTLs in a wide range of tissues of relevance to many diseases. But the
value of a large GTEx resource, especially one that includes other molecular phenotypes,
goes well beyond GWAS follow-up, by providing a deeper understanding of the functional
elements of the genome and their underlying biological mechanisms.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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BOX 1 – Goals of the GTEx Project
• To create a data resource to enable the systematic study of genetic variation and
the regulation of gene expression in multiple reference human tissues
• To provide the scientific community with a biospecimen resource including
tissue, nucleic acid, and cell lines upon which to determine other molecular
phenotypes
• To support and disseminate the results of a study of the ethical, legal, and social
issues related to donor recruitment and consent.
• To support the development of novel statistical methods for the analysis of
human expression Quantitative Trait Loci (eQTL) alone and in the context of
other molecular phenotypes.
• To make the data available to the research community as rapidly as possible.
• To support the dissemination of knowledge, standards, and protocols related to
biospecimen collection and analysis methods developed during the project.
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Figure 1.
Effect of sample size and MAF on power to detect eQTLs. (a) Power for cis-eQTL analysis in which we assume α =
0.05/200,000, reflecting Bonferroni correction for 200,000 hypotheses based on 20,000 genes and an average of 10 non-
redundant SNPs in the region ±100 kb of each gene. (b) Power for trans-eQTL analysis in which we test 20,000 genes against 5
million SNPS in a total of 1 × 1011 tests with α = 5 × 10−13.
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